135P - A multicenter retrospective observation study about overall survival benefit of eribulin mesylate in comparison with taxane regimens for metastatic...

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer Agents
Breast Cancer, Metastatic
Presenter Yasuko Kikuchi
Citation Annals of Oncology (2016) 27 (suppl_9): ix35-ix41. 10.1093/annonc/mdw577
Authors Y. Kikuchi1, Y. Uchida2, H. Kanauchi3, T. Niwa1, K. Nishioka1, K. Tada1, M. Hashimoto4, H. Yasuda4, H. Kawabata5, Y. Seto1, T. Ogawa6
  • 1Breast And Endocrine Surgery, University of Tokyo, 113-8655 - Tokyo/JP
  • 2Breast Center, International University of Health and Welfare Mita Hospital, 108-8329 - Tokyo/JP
  • 3Breast Center, Showa General Hospital, 187-8510 - Tokyo/JP
  • 4Surgery, National Center for Global Health and Medicine, 162-8655 - Tokyo/JP
  • 5Breast And Endocrine Surgery, Toranomon Hospital, 105-8470 - Tokyo/JP
  • 6Breast Center, Dokkyo Medical University Koshigaya Hospital, 343-8555 - Saitama/JP



Eribulin (Eri) has been reported to prolong overall survival (OS) in several studies with metastatic breast cancer (MBC) patients (pts). Recently, some reports have showed OS benefit in Eri comparison with taxane regimens for the early line MBC pts. Here we presented an analysis about the OS extension effect of Eri in a retrospective multicenter observation study for MBC pts.


MBC pts who received eribulin or taxanes in the early line treatment from August 2011 to March 2014 in our institutes were analyzed. Taxane regimens included monotherapy of paclitaxel, docetaxel, nab-paclitaxel and the taxane combination with bevacituzumab. The efficacy including complete response (CR) and objective response rate (ORR) and adverse events were determined. Kaplan-Meier method was utilized to estimate median OS and survival post progression (SPP). And subgroup analysis of OS was by tumor subtypes and treatment-line.


A total 221 patients were analyzed included in this study and 101 pts received eribulin and 120 pts received taxanes. ORR was higher in eribulin than taxanes (49.5% vs 21.7%) and CR rate was 11% in eribulin and 0.4% in taxanes. The median OS and SPP were longer in eribulin than taxanes (OS: 22.3 months vs 13.6 months, SPP: 14.0 months vs 7.7 months). Subgroup analysis showed tendency of longer OS in MBC pts who had ER positive and visceral metastases, and who received in early line treatment. The major reason for discontinuing Eri treatment was due to increase of primary tumor size. Adverse events had been observed lower in Eri (1.0%) than in taxanes (16.0%). The study also found that the incidence of distant metastases at the time of PD was lower in patients receiving eribulin (11.3%) compared with those receiving taxanes (28.3%). Mean number of treatment regimens after the study therapy were 2.4 in eribulin and 1.5 in taxanes.


From those analysis, the higher efficacy and acceptable safety profile of eribulin might contribute to prolonged survival.

Clinical trial indentification

Legal entity responsible for the study





All authors have declared no conflicts of interest.